

INVIVO THERAPEUTICS HOLDINGS CORP.

Form 8-K

July 08, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 7, 2011

INVIVO THERAPEUTICS HOLDINGS CORP.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction

of incorporation)

000-52089
(Commission

File No.)

36-4528166
(IRS Employer

Identification No.)

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 8-K

One Broadway, 14th Floor

Cambridge, Massachusetts
(Address of principal executive offices)

(617) 475-1520

02142
(Zip Code)

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On July 7, 2011, InVivo Therapeutics Holdings Corp. (the Registrant) issued a press release announcing that the Registrant submitted an Investigational Device Exemption to the U.S. Food and Drug Administration for a proprietary biopolymer scaffolding device to protect and support spinal tissue and prevent secondary injury following traumatic spinal cord injury. A copy of the press release is filed as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The exhibit listed in the Exhibit Index below is filed with this report.

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

InVivo Therapeutics Holdings Corp.

Date: July 8, 2011

By: /s/ Frank M. Reynolds
Frank M. Reynolds
Chief Executive Officer

EXHIBIT INDEX

Exhibit

No.	Description	Title	Date
99.1	Press Release of the Registrant, dated July 7, 2011.		
	ge Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.		
	Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.		
	/s/ J. Thomas Wilson	President and Chief Executive Officer, and Director (Principal Executive Officer)	June 26, 2013
	John Thomas Wilson		
	/s/ Antoine J. Lafargue	Vice President - Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)	June 26, 2013
	Antoine J. Lafargue		
	/s/ Vadim Gluzman	Director	June 26, 2013
	Vadim Gluzman		
	/s/ Robert I. Israel	Director	June 26, 2013
	Robert I. Israel		
	/s/ Brendan S. MacMillan	Director	June 26, 2013
	Brendan S. MacMillan		
	/s/ Walter McCann	Director	June 26, 2013
	Walter McCann		
	/s/ Ronald P. Pettirossi	Director	June 26, 2013
	Ronald P. Pettirossi		
	/s/ Milam Randolph Pharo	Director	June 26, 2013
	Milam Randolph Pharo		
	/s/ J. Robinson West	Director	June 26, 2013
	J. Robinson West		

Exhibit Index

Exhibit No.	Description
5.1	Opinion of Ballard Spahr LLP
23.1	Consent of EKS&H LLLP
23.2	Consent of Deloitte & Touche LLP
23.3	Consent of Allen & Crouch Petroleum Engineers Inc.
23.4	Consent of Ryder Scott Company, L.P.
99.4	Nonqualified Stock Option Award and Subscription Agreement between Magellan Petroleum Corporation and Wesson Liversage dated January 10, 2012
99.6	Nonqualified Stock Option Award and Subscription Agreement between Magellan Petroleum Corporation and Chris Peterson dated December 4, 2012
99.7	Nonqualified Stock Option Award and Subscription Agreement between Magellan Petroleum Corporation and Kristin Keller dated December 4, 2012